PDUFA and BsUFA Quarterly Hiring Updates
As part of the reauthorizations of the Prescription Drug User Fee Act (PDUFA VII) and the Biosimilar User Fee Act (BsUFA III), the Food and Drug Administration (FDA) committed to reporting quarterly updates on the progress made towards hiring goals for fiscal years (FY) 2023-2027. Tables will be added for each FY (2023-2027) below and updated quarterly.
FY23 Hiring Goals
The tables below represent the outstanding hiring goals from FY 2023 for PDUFA VII and BsUFA III and FDA’s completion percentage of those hiring goals as of March 31, 2023.
PDUFA VII |
FY 2023 Hiring Goals |
Q1 (12/31/2022) |
Q2 (3/31/2023) |
Q3
|
Q4
|
Total |
Percentage complete |
Center for Biologics Evaluation and Research (CBER) |
132 |
58** |
17 |
- |
- |
75 |
57% |
Center for Drug Evaluation and Research (CDER) |
77 |
13** |
13 |
- |
- |
26 |
34% |
Other FDA |
1 |
0 |
1 |
- |
- |
1 |
100% |
TOTAL Full Time Equivalents (FTEs) |
210 |
71 |
31 |
- |
- |
102 |
49% |
BsUFA III |
FY 2023 Hiring Goals |
Q1 (12/31/2022) |
Q2 (3/31/2023) |
Q3
|
Q4
|
Total |
Percentage complete |
Center for Drug Evaluation and Research (CDER) |
14 |
3 |
1 |
- |
- |
4 |
29% |
TOTAL Full Time Equivalents (FTEs) |
14 |
3 |
1 |
- |
- |
4 |
29% |
*A hire is defined as someone who has been confirmed as on board by the date indicated in a full-time position at the noted Center. While some hires are recruited from outside the Center/FDA, in some cases a hire can also be a current Center/FDA employee who is changing positions within the agency.
**Totals include some PDUFA VII hiring completed prior to FY 2023.